2 results
Approved WMOCompleted
To assess the safety and tolerability profile of LJN452 and to determine the early hepatic response to different doses of LJN452 in patients with phenotypic non-alcoholic steatohepatitis (NASH). Data from this study will be used to support further…
Approved WMOCompleted
Primary Objective:• To create a population pharmacokinetic model of SARS-COV-2 neutralizing antibodies as present in ConvP.• To create a population pharmacokinetic model of SARS-COV-2 neutralizing antibodies as present in Nanogam*plusSecondary…